|A taxonomy of model structures for economic evaluation of health technologies|
A Brennan, SE Chick, R Davies
Health economics 15 (12), 1295-1310, 2006
|Screening for type 2 diabetes: literature review and economic modelling|
N Waugh, G Scotland, P McNamee, M Gillett, A Brennan, E Goyder, ...
HEALTH TECHNOLOGY ASSESSMENT-SOUTHAMPTON- 11 (17), 2007
|Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–4|
J Karnon, J Stahl, A Brennan, JJ Caro, J Mar, J Möller
Medical decision making 32 (5), 701-711, 2012
|Estimated effect of alcohol pricing policies on health and health economic outcomes in England: an epidemiological model|
RC Purshouse, PS Meier, A Brennan, KB Taylor, R Rafia
The Lancet 375 (9723), 1355-1364, 2010
|Effects of minimum unit pricing for alcohol on different income and socioeconomic groups: a modelling study|
J Holmes, Y Meng, PS Meier, A Brennan, C Angus, A Campbell-Burton, ...
The Lancet 383 (9929), 1655-1664, 2014
|Accurate, practical and cost-effective assessment of carotid stenosis in the UK.|
JM Wardlaw, FM Chappell, M Stevenson, E De Nigris, S Thomas, J Gillard, ...
Health Technology Assessment (Winchester, England) 10 (30), iii-iv, ix, 2006
|Policy options for alcohol price regulation: the importance of modelling population heterogeneity|
PS Meier, R Purshouse, A Brennan
Addiction 105 (3), 383-393, 2010
|Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness …|
M Gillett, HM Dallosso, S Dixon, A Brennan, ME Carey, MJ Campbell, ...
Bmj 341, 2010
|Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK|
A Brennan, N Bansback, A Reynolds, P Conway
Rheumatology 43 (1), 62-72, 2004
|Modelling in health economic evaluation|
A Brennan, R Akehurst
Pharmacoeconomics 17 (5), 445-459, 2000
|Using mixed treatment comparisons and meta‐regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis|
RM Nixon, N Bansback, A Brennan
Statistics in medicine 26 (6), 1237-1254, 2007
|Should patients have a greater role in valuing health states?|
J Brazier, R Akehurst, A Brennan, P Dolan, K Claxton, C McCabe, ...
Applied health economics and health policy 4 (4), 201-208, 2005
|Estimating multiparameter partial expected value of perfect information from a probabilistic sensitivity analysis sample: a nonparametric regression approach|
M Strong, JE Oakley, A Brennan
Medical Decision Making 34 (3), 311-326, 2014
|Non-pharmacological interventions to reduce the risk of diabetes in people with impaired glucose regulation: a systematic review and economic evaluation.|
M Gillett, P Royle, A Snaith, G Scotland, A Poobalan, M Imamura, C Black, ...
Health technology assessment, 2012
|Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden|
NJ Bansback, A Brennan, O Ghatnekar
Annals of the rheumatic diseases 64 (7), 995-1002, 2005
|Modelling the cost effectiveness of TNF-α antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry|
A Brennan, N Bansback, R Nixon, J Madan, M Harrison, K Watson, ...
Rheumatology 46 (8), 1345-1354, 2007
|The efficacy of inhibiting tumour necrosis factor α and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons|
R Nixon, N Bansback, A Brennan
Oxford University Press 46 (7), 1140-1147, 2007
|Calculating partial expected value of perfect information via Monte Carlo sampling algorithms|
A Brennan, S Kharroubi, A O'hagan, J Chilcott
Medical Decision Making 27 (4), 448-470, 2007
|Home telemonitoring or structured telephone support programmes after recent discharge in patients with heart failure: systematic review and economic evaluation.|
A Pandor, P Thokala, T Gomersall, H Baalbaki, JW Stevens, J Wang, ...
Health Technology Assessment (Winchester, England) 17 (32), 1, 2013
|Biologic drugs for rheumatoid arthritis in the Medicare program: a cost‐effectiveness analysis|
AJ Wailoo, N Bansback, A Brennan, K Michaud, RM Nixon, F Wolfe
Arthritis & Rheumatism 58 (4), 939-946, 2008